Embecta Showcases Its Insulin Patch Pump at ADA Event
Embecta, a company previously known for manufacturing pen needles and insulin syringes, has made strides in the development of an insulin patch pump specifically designed for individuals with Type 2 diabetes. The company showcased two abstracts at the recent American Diabetes Association Scientific Sessions, which spotlighted the need and effectiveness of their new patch pump […]
Grail Embarks Independently in the Public Markets Following Completion of Illumina Spin-Off
Cancer test maker Grail made its debut on the Nasdaq on Tuesday, marking a significant pivot nearly four years after its initial public offering plans were disrupted by a takeover from Illumina. This development follows a prolonged period of regulatory disputes involving both the U.S. Federal Trade Commission and the European Commission, which challenged the […]
Managing Medical Device Projects with Paper Systems: A High-Risk Approach
Despite the prevalence of modern document management options, many startup medical device companies surprisingly still rely on traditional methods such as paper records and “digital paper” tools like spreadsheets, Dropbox, and other general-purpose software. These methods pose significant risks to both business operations and product quality within a Quality Management System (QMS). There are inherent […]
Insulet aims to expand Omnipod 5 labeling to include Type 2 diabetes.
Insulet, a prominent player in the diabetes care sector, is actively seeking to broaden the use of its Omnipod 5 insulin pump to include individuals with Type 2 diabetes after its recent regulatory submission to the U.S. Food and Drug Administration (FDA). The move could significantly impact the treatment landscape for the 30 million Americans […]
FDA completes plan to regulate certain laboratory-developed tests
The Food and Drug Administration (FDA) has announced that it will begin actively regulating tests developed in laboratories, with some exemptions. This decision comes after Congress failed to pass a law regulating these tests, which have grown in power and complexity over the years. The agency’s move is motivated by concerns about tests like Theranos’ […]
Exclusive Article | Thank You
The Federal Food, Drug, and Cosmetic Act prohibits facilities from denying, delaying, or limiting FDA inspections, or their products may be considered adulterated. This policy has been in place for drug facilities since 2012, but was only extended to medical devices in 2017 under the FDA Reauthorization Act. The FDA has finalized a revision to […]
Tracking Risky Medical Devices: How Kaiser Permanente Hospitals Stay Vigilant
When new medical devices are approved by the FDA, there is still uncertainty about their effectiveness. Unlike biotech products, device makers do not have to provide as much clinical data for approval. After approval, tracking device performance in the real world is challenging due to lack of comprehensive databases and difficulties in tracking unique device […]
Roche Announces New Neuro Alliance, Signs R&D Agreement with RNA-Editing Startup Ascidian
Roche, a pharmaceutical company, has entered into a partnership with Ascidian Therapeutics, a startup focusing on RNA editing technology in genetic medicine. This $42 million deal allows Roche to use Ascidian’s RNA exon-editing technology for certain neurological targets that have severe unmet medical needs. Ascidian’s approach to genetic medicine involves editing exons to replace mutated […]
FDA Releases Official Guidance Granting Extended Inspection Authority to Medical Devices | Exclusive FDA Today Feature
The Federal Food, Drug and Cosmetic Act prohibits facilities from denying, delaying or limiting FDA inspections in order to prevent their products from being considered adulterated. This policy has been in place for drug facilities since 2012, but was only extended to medical devices in 2017. The FDA has recently finalized a revision to its […]
Akili Interactive, creator of digital therapeutics, reveals downsizing efforts
Akili Interactive, a company known for its video game treatment for attention deficit hyperactivity disorder (ADHD), is facing challenges as it struggles with sluggish sales. In response to this, the company has announced that it will lay off 46% of its staff and explore strategic alternatives. This decision comes after other digital therapeutics companies, such […]